Company Of The Day: Merck
What?
Merck (NYSE:MRK) is preparing a new formulation for its blockbuster cancer immunotherapy Keytruda, which could be injected under the skin.
Why?
- Is An Earnings Beat In The Cards For Merck Stock?
- With Robust AI Prospects Is IBM A Better Pick Over Merck Stock Within The Dow Index?
- Is Johnson & Johnson Stock A Better Pick Over Merck?
- Is Merck Stock Fully Valued At $130?
- Will Higher Keytruda Sales Drive Merck’s Q1
- After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
Keytruda will see patents start to expire in 2028. Merck believes that the new formulation has the potential to be novel, non-obvious, and useful, implying that it could receive a new patent.
So What?
Keytruda is Merck’s most important drug, generating over $17 billion in sales in 2021. These developments could potentially help the company hold off on a sales decline.
See Our Complete Analysis For Merck
| Returns | Dec 2022 MTD [1] |
2022 YTD [1] |
2017-22 Total [2] |
| MRK Return | 0% | 44% | 87% |
| S&P 500 Return | 0% | -15% | 82% |
| Trefis Multi-Strategy Portfolio | 1% | -17% | 230% |
[1] Month-to-date and year-to-date as of 12/5/2022
[2] Cumulative total returns since the end of 2016